По вашему запросу найдено документов: 78

Страница 1 из 8

ЗДРАВООХРАНЕНИЕ ВО ВРЕМЯ И ПОСЛЕ ПАНДЕМИИ COVID-19
HEALTH CARE DURING AND AFTER COVID-19
ТИМЕРБУЛАТОВ, В.М., ТИМЕРБУЛАТОВ, М.В., TIMERBULATOV, V.M., TIMERBULATOV, M.V. (2020)
LEGISLATIVE ACTS
Political Communications of the UK Government as an Institutional System
Ivanova, OM, Guryev, ME, Sadykova, ZR, Mingazova, NR, Khramova, KV (2021)
, the state as a governing body, represented by three powers: legislative, executive, and judicial. Secondly
АНАЛИЗ ОСОБЕННОСТЕЙ СТРУКТУРЫ ЗАКУПОК ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ НА РЕГИОНАЛЬНОМ УРОВНЕ В РОССИЙСКОЙ ФЕДЕРАЦИИ
ANALYSIS OF FEATURES OF MEDICATION SUPPLY STRUCTURE IN THE RUSSIAN FEDERATION AT THE REGIONAL LEVEL
Мироненкова, Ж.В., Умаров, С.З., Кныш, О.И., Габдулхакова, Л.М., Эль Муссави, М.А.Э.Х., Mironenkova, Zhanna. V., Umarov, Sergey. Z., Knysh, Olga. I., Gabdulkhakova, Lyaysan. M., El’ Mussavi, A. E. Kh. Mokhamad. (2023)
A RANDOMIZED PHASE 2 STUDY OF LONG-ACTING TRANSCON GH VS DAILY GH IN CHILDHOOD GH DEFICIENCY
Chatelain, Pierre, Malievskiy, Oleg, Radziuk, Klaudziya, Senatorova, Ganna, Abdou, Magdy O., Vlachopapadopoulou, Elpis, Skorodok, Yulia, Peterkova, Valentina, Leff, Jonathan A., Beckert, Michael (2017)
Context: TransCon Growth Hormone (GH) (Ascendis Pharma) is a long-acting recombinant sustained
LONG-ACTING C-TERMINAL PEPTIDE-MODIFIED HGH (MOD-4023): RESULTS OF A SAFETY AND DOSE-FINDING STUDY IN GHD CHILDREN
Zelinska, N., Iotova, V., Skorodok, J., Malievsky, O., Peterkova, V., Samsonova, L., Rosenfeld, Ron G., Zadik, Zvi, Jaron-Mendelson, Michal, Koren, Ronit, Amitzi, Leanne, Raduk, Dmitri, Hershkovitz, Oren, Hart, Gili (2017)
LONG-ACTING C-TERMINAL PEPTIDE-MODIFIED HGH (MOD-4023): RESULTS OF A SAFETY AND DOSE-FINDING STUDY
Widespread natural selection on metabolite levels in humans
Timasheva, Yanina, Lepik, Kaido, Liska, Orsolya, Papp, Balázs, Kutalik, Zoltán (2024)
Natural selection acts ubiquitously on complex human traits, predominantly constraining
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
Deal, C, Steelman, J, Vlachopapadopoulou, E, Stawerska, R, Silverman, LA;, Phillip, M, Kim, HS, Ko, CW, Malievskiy, O, Cara, JF, Roland, CL, Taylor, CT, Valluri, SR, Wajnrajch, MP, Pastrak, A, Miller, BS (2022)
Context: Somatrogon is a long-acting recombinant human growth hormone (rhGH) in development
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
Maniatis, AK;, Casella, SJ;, Nadgir, UM;, Hofman, PL;, Saenger, P;, Chertock, ED;, Aghajanova, EM;, Korpal-Szczyrska, M;, Vlachopapadopoulou, E;, Malievskiy, O;, Chaychenko, T;, Cappa, M;, Song, WJ;, Mao, M;, Mygind, PH;, Smith, AR;, Chessler, S;, Komirenko, AS;, Beckert, M;, Aimee, D Shu, Paul, S Thornton (2022)
the long-term safety and efficacy of weekly administered long-acting growth hormone lonapegsomatropin
An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment
Zadik, Zvi, Zelinska, Nataliya, Iotova, Violeta, Skorodok, Yulia, Malievsky, Oleg, Mauras, Nelly, Valluri, Srinivas Rao, Pastrak, Aleksandra, Rosenfeld, Ron (2023)
Objectives: Somatrogon is a long-acting recombinant human growth hormone (GH) employed as a once
АНАЛИЗ ПРАВОВОГО РЕГУЛИРОВАНИЯ РЕКЛАМИРОВАНИЯ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ ДЛЯ ПРОФИЛАКТИЧЕСКОГО ПРИМЕНЕНИЯ
THE ANALYSIS OF LEGAL REGULATION OF ADVERTISING OF MEDICINES FOR PROPHYLACTIC USE
МАКАРОВ, Р.П., MAKAROV, R.P. (2022)

Страница 1 из 8

Google Scholar
OpenDoar

Фасеты

Научный руководитель
Авторы
Ключевые слова
Год